BSD-2000 PMA
This article was originally published in The Gray Sheet
Executive Summary
BSD Medical submits premarket approval application for tumor hyperthermia therapy May 22. The PMA is based on data from approximately 4,000 treatments of more than 800 patients (1"The Gray Sheet" Jan. 19, 2006, p. 15). The device employs an array of radiofrequency antennae to generate enough energy to target and kill cancer cells...